Diseases such as Alzheimer's disease, asthma, cardiovascular disease, depression, gastrointestinal disease, HIV/AIDS, infectious disease, and migraine cast a significant burden of employees on United States employers. The purpose of this study was to critically review published literature on the burden of diseases. The results indicate that there are very few studies published with data on the burden of illness on United States employers. Only 35 articles were found discussing indirect costs of illness such as absenteeism, productivity, short- or long-term disability (STD, LTD) and drug costs. Interpretation of these cost analyses is limited because of variation in methodology and measures between the studies. These include monetary and nonmonetary measures, obtained from different groups of patients using different techniques. Although the results confirm that these diseases have a significant impact on employers, there is no standardized measure to quantitate this impact. The current state of the literature suggests that primary research studies should be conducted with large firms or organizations to determine the actual impact of employee illness.
ContiDJBurtonWNThe economic impact of depression in a workplace. J Occupation Med.1994;36:983–988.
2.
FarnhamPGGorskyRDCosts to business for an HIV-infected worker. Inquiry.1994;31:76–88.
3.
LeighJPLubeckDPFarnhamPPotential and actual workdays lost among patients with HIV. J Acquired Immune Deficiency Syndromes Human Retrovirology.1995;8:392–398.
4.
LeggRFSclarDANemecNLCost benefit of sumatriptan to an employer. J Occupation Environment Med.1997;39:652–657.
5.
WeissKBGergenPJHodgsonTAAn economic evaluation of asthma in the United States. New Engl J Med.1992;326:862–866.
6.
WeissK.The impact of pharmacologic therapy on the costs of asthma. Allergy Proceed.1994;15:189–192.
7.
SmithDHMaloneDCLawsonKAA national estimate of the economic costs of asthma. Am J Respiratory Critical Care Med.1997;156:787–793.
8.
TaitelMSKotsesHBernsteinILA self-management program for adult asthma. Part II: Cost-benefit analysis. J Allergy Clin Immunol.1995;95: 672–676.
9.
SteinwachsDMWuASkinnerEAYoungYCampbellD.Asthma patient outcomes study; baseline survey summary report. Managed Health Care Association Outcomes Management System Project. Bloomington, MN, Health Outcomes Institute [Stratis Health; 1995].
10.
BlancPDJonesMBessonCWork disability among adults with asthma. Chest Vol.1993;104: 1371–1377.
11.
FoxPGazzanigaJKarterAThe economic costs of cardiovascular disease mortality in California, 1991: implications for public health policy. J Public Health Policy.1996;17:442–459.
12.
OdellTWGregoryMCCost of hypertension treatment. J General Int Med.1995;10:686–688.
13.
ElliottWJThe costs of treating hypertension: what are the long-term realities of cost containment and pharmacoeconomics?Postgraduate Med.1996;99: 241–248.
14.
HillemanDEMohiuddinSMLucasBDJCost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Therapeutics.1994;16:88–102.
15.
WolfAMColditzGAThe cost of obesity: the US perspective. Pharmacoecono.1994;5:34–37.
16.
GreenbergPEStiglinLEFinkelsteinSNThe economic burden of depression in 1990. J Clin Psychiatry.1993;54:405–418.
17.
StoudemireAFrankRHedemarkNThe economic burden of depression. General Hospital Psychiatry.1986;8:387–394.
18.
FinkelsteinSNBerndtERGreenbergPEImprovement in subjective work performance after treatment of chronic depression: Some preliminary results. Psychopharmacology Bull.1996;32:33–40.
19.
JuddLLPaulusMPWellsKBSocioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry.1996;153:1411–1417.
20.
SimonGEVonKorffMBarlowW.Health care costs of primary care patients with recognized depression. Arch General Psychiatry.1995;52:850–856.
21.
HenkHJKatzelnickDJKobakKAMedical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch General Psychiatry.1996;53:899–904.
22.
JohnsonJWeissmanMMKlermanGLService utilization and social morbidity associated with depressive symptoms in the community. JAMA.1992;267:1478–1483.
23.
BroadheadWEBlazerDGGeorgeLKDepression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA.1990;264:2524–2528.
24.
SonnenbergAEverhartJEHealth impact of peptic ulcer in the United States. Am J Gastroenterol.1997;92:614–620.
25.
YelinEHGreenblattRMHollanderHThe impact of HIV-related illness on employment. Am J Public Health.1991;81:79–84.
26.
SebestaDSLaPlanteMPHIV/AIDS, disability, and employment. Disability Statistics Report (9). Washington, DC: US Department of Education, National Institute on Disability and Rehabilitation Research. 1996;20202–20264.
27.
LeighJPLubeckDPFarnhamPGHours at work and employment status among HIV-infected patients. AIDS.1995;9:81–88.
28.
HellingerFJThe lifetime cost of treating a person with HIV. JAMA.1993;270:474–478.
29.
SchwartzBSStewartWFLiptonRBLost workdays and decreased work effectiveness associated with headache in the workplace. J Occupational Environmental Med.1997;39:320–327.
30.
StewartWFLiptonRBSimonD.Work-related disability: results from the American migraine study. Cephalalgia.1996;16:231–238.
31.
LinetMSStewartWFCelentanoDDAn epidemiologic study of headache among adolescents and young adults. JAMA.1989;261:2211–2216.
32.
StewartWFCelentanoDDLinetMSDisability, physician consultation, and use of prescription medications in a population-based study of headache. Biomed Pharmacother.1989;43:711–718.
33.
JhingranPCadyRKRubinoJImprovements in health-related quality of life with sumatriptan treatment for migraine. J Family Practice.1996;42: 36–42.
34.
MushetGRMillerDClementsBImpact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache.1996;36:137–143.
35.
StangPEOsterhausJTImpact of migraine in the United States: data from the National Health Interview Survey. Headache.1993;33:29–35.
